Cell line · CVCL_0076
Papers46
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 46
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| CRACD loss drives hypoxia-induced immune escape in gastric cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Role of NADPH Oxidase 4 in Neutrophil-Mediated Immune Escape in Gastric Cancer. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. | FEBS Open Bio | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Analysis of RHOA mutations and their significance in the proliferation and transcriptome of digestive tract cancer cells. | Oncol Lett | 2021 | Cellosaurus cites it | PubMed | |
| The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer. | Int J Mol Sci | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0076/papers